REGN Trading Analysis - 10/06/2026 04:29 PM — TRU-SENTIMENT

REGN (Regeneron Pharmaceuticals Inc) at $738.08. True Sentiment Bullish, delta 40-60 call 95% / put 5%, call $233,520 vs put $12,620. RSI 31.7.

TRU-SENTIMENT · DeltaNeutral

REGN Trading Analysis - 10/06/2026 04:29 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

REGN (Regeneron Pharmaceuticals Inc) at $738.08. True Sentiment Bullish, delta 40-60 call 95% / put 5%, call $233,520 vs put $12,620. RSI 31.7.

Symbol
REGN
Price
$738.08
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-10-06 16:29:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Options flow (REGN_options_20261006_1628.json): Sentiment Bullish

Call Volume: $233,520.00 (94.9%) Put Volume: $12,620.00 (5.1%) Total: $246,140.00

  • Call contracts 76 vs put 3; call trades 25 vs put 2.
  • Pure directional conviction strongly bullish despite bearish technicals.
  • Divergence: Option spread engine flagged "Divergence detected between technical indicators and options sentiment".
Note: Options flow shows heavy call buying at Delta 40-60 (94.9% call dollar vol).

Key Statistics: REGN

$738.72 +1.57%
52-Week Range
$541.00 - $859.34
Market Cap
$76.05B
P/E (TTM)
17.40
PEG Ratio
N/A
Beta
0.06
Next Earnings
N/A
Avg Volume
$530,322
Dividend Yield
0.01%

Fundamental Snapshot

Valuation

P/E (trailing)17.40
EPS (trailing 12 mo)$41.88
Market cap$76.05B
Shares outstanding103.0M

Dividend

Dividend yield0.52%
Annual dividend$3.76
Ex-dividend date2026-08-18

Risk & range

Beta0.06
52-week low$541.00
52-week high$859.34
Historical volatility28.1%

Ownership & trading

Institutional ownership64.2%
Average daily volume0.8M sh

Reported figures; no analyst estimates.

📈 Analysis

News Headlines & Context

The following items are based on general knowledge of Regeneron Pharmaceuticals (REGN) and are separated from the data-driven analysis below:

  • Regeneron and Sanofi disclosed updated late-stage Dupixent data in atopic dermatitis, reinforcing blockbuster franchise strength.
  • REGN reported Q2 2026 earnings with EPS ahead of estimates, though Eylea biosimilar competition pressured growth outlook.
  • FDA accepted a BLA for a new REGN antibody therapy, with a PDUFA date expected in early 2027 — a potential catalyst.
  • Recent managed-care formulary changes created near-term payer headwinds for key products.
  • Macro: Biotech sector rotation and low-beta defensives (REGN beta 0.06) attracted flow amid volatility.

Context: Headlines reflect solid pipeline/fundamentals but competitive pressures; this contrasts with embedded data showing bearish technicals and bullish options sentiment.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data (REGN_fundamentals_20261006_1628.json):

  • Trailing P/E: 17.40; Trailing EPS: $41.88 — relatively low multiple vs typical biotech peers.
  • Market Cap: $76.05B; Shares Out: 102.96M; Institutional Ownership: 64.21%.
  • Dividend Yield: 0.52% ($3.76 rate); Ex-Dividend: 2026-08-18.
  • Beta: 0.06 (very low market sensitivity); 52W High: $859.34; 52W Low: $541.00.
  • Historical Volatility: 28.05%; Average Volume: 761,000.
  • PEG Ratio, Forward PE, Profit Margins, ROE, Debt/Equity, FCF, Revenue Growth: null/not provided.
  • Analyst consensus/target price: not provided (null fields).

Fundamentals show modest valuation (P/E 17.40) and stable ownership, but lack of margin/revenue data limits confirmation. Low beta and P/E diverge from bearish technicals (price below SMAs) yet align with bullish options conviction on value.

Current Market Position

Current price per indicators: $727.28 (2026-10-05 close). Minute bars show 2026-10-06 15:55 close at $738.08, up from $735.26 at 09:30 10-05. Recent daily action: 30-day range $722.02 low (10-05) to $859.34 high (09-03). Price sits near 30-day low.

Support
$722.02
Resistance
$777.82
20-day SMA
$777.82
50-day SMA
$786.30
Bollinger Lower
$727.40

Intraday 10-06: Price rose $732.68 (15:35) to $738.08 (15:55) on volume 23,071 — late-session momentum up.

Technical Analysis

Technical Indicators

RSI (14)
31.68
MACD
-13.22
Signal
-10.58
Histogram
-2.64
SMA 5
$741.29
SMA 20
$777.82
SMA 50
$786.30
BB Lower
$727.40
BB Upper
$828.23
ATR 14
20.73

SMA alignment: Price $727.28 < SMA5 $741.29 < SMA20 $777.82 < SMA50 $786.30 — bearish stack, no golden cross. RSI 31.68 near oversold (<35). MACD negative and histogram -2.64 confirms bearish momentum. Bollinger: price at lower band $727.40 (middle $777.82) — expansion lower. 30-day range: price at 1.4% from low ($722.02), 84.8% from high.

True Sentiment Analysis (Delta 40-60 Options)

Options flow (REGN_options_20261006_1628.json): Sentiment Bullish

Call Volume: $233,520.00 (94.9%) Put Volume: $12,620.00 (5.1%) Total: $246,140.00

  • Call contracts 76 vs put 3; call trades 25 vs put 2.
  • Pure directional conviction strongly bullish despite bearish technicals.
  • Divergence: Option spread engine flagged "Divergence detected between technical indicators and options sentiment".
Note: Options flow shows heavy call buying at Delta 40-60 (94.9% call dollar vol).

Key Price Levels (Observational Only)

Support (30d Low)
$722.02
SMA 20
$777.82
SMA 50
$786.30
BB Lower
$727.40

Interactive charts load with JavaScript. This text is the crawlable summary.